Patent ID: 8883863

Claim:
A pharmaceutical drug product comprising at least one drug substance selected from the group consisting of: amorphous sibutramine pamoate characterized by at least one method selected from: a PXRD diffractogram of FIG. 1 ; a DSC thermogram of FIG. 5 ; and an FTIR spectrum of FIG. 3 ; polymorphic sibutramine pamoate characterized by at least one method selected from: a PXRD diffractogram of FIG. 2 ; a DSC thermogram of FIG. 6 ; and an FTIR spectrum of FIG. 4 ; amorphous nortriptyline pamoate characterized by at least one method selected from: a DSC thermogram of FIG. 9 ; and an FTIR spectrum of FIG. 11 ; polymorphic nortriptyline pamoate characterized by at least one method selected from: a DSC thermogram of FIG. 10 ; and an FTIR spectrum of FIG. 12 ; amorphous clomipramine pamoate characterized by at least one method selected from: a PXRD diffractogram of FIG. 16 ; a DSC thermogram of FIG. 20 ; and an FTIR spectrum of FIG. 18 ; polymorphic clomipramine pamoate characterized by at least one method selected from: a PXRD diffractogram of FIG. 17 ; a DSC thermogram of FIG. 21 ; and an FTIR of FIG. 19 ; amorphous promethazine pamoate characterized by at least one method selected from: a PXRD diffractogram of FIG. 26 ; a DSC thermogram of FIG. 32 ; an FTIR spectrum of FIG. 29 ; a PXRD diffractogram of FIG. 27 ; a DSC thermogram of FIG. 33 ; and an FTIR spectrum of FIG. 30 ; and polymorphic promethazine pamoate characterized by at least one method selected from: a PXRD diffractogram of FIG. 28 ; a DSC thermogram of FIG. 34 ; and an FTIR spectrum of FIG. 31 .